What is the main business of Chiesi Poland?

The main business activity of Chiesi Poland focuses on wholesale of pharmaceutical goods.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on December 13, 2004.

Where is the headquarters located?

The headquarters is located at: Al. Aleje Jerozolimskie 134, 02-305 Warszawa.

What is the share capital?

The share capital of the company is PLN 14,000,000 (approx. $3.8 million).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2022 to December 31, 2022.

What was the revenue?

The company reported a revenue of $63,525,987 in 2022, which is an increase of 13.4% compared to 2021.

Is the company profitable?

Yes, in 2022 the company was profitable, achieving a net profit of $1,782,255, meaning the company decreased its profit by 1.1%.

Which cost dominates operating expenses?

The largest operating cost category falls under cost of goods and materials sold. This category amounted to $44,356,391 in 2022, representing 73% of all operating expenses.

Chiesi Polandsp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2004-12-13

Share capital

14 000 000,00 PLN

Activity description

Chiesi Poland operates in the pharmaceutical industry and offers prescription medicines and over-the-counter products. Its therapeutic areas include respiratory medicine, neonatology, transplantology and pediatrics; the company also conducts research and development.

Registered address

al. Aleje Jerozolimskie 134, 02-305 Warszawa, Poland

Website

chiesi.pl

Phone

Electronic delivery address

AE:PL-38624-60827-WRJWS-29

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 87.76mMedianUSD 874.80kAverageUSD 20.30m

Net profit

This companyUSD 2.95mMedianUSD 28.22kAverageUSD 816.54k

Operating costs

This companyUSD 83.95mMedianUSD 805.63kAverageUSD 19.09m

Assets

This companyUSD 40.48mMedianUSD 541.73kAverageUSD 10.95m

Industry

Bank accounts

Registered as a VAT taxpayer on 2004-12-28. Active

Citi Handlowy (Bank Handlowy w Warszawie)
03 1030 1508 0000 0008 1895 2003
Citi Handlowy (Bank Handlowy w Warszawie)
57 1030 1508 0000 0008 1895 2001
Citi Handlowy (Bank Handlowy w Warszawie)
84 1030 1508 0000 0008 1895 2000

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

No public aid cases recorded in the last 10 years.

Tenders

No recorded participation in tenders.

Trademarks

Chiesi Poland holds 11 active trademarks registered with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2015.

Mark	Number	Classes	Status	Protected until
Innofer Immuno(word)	Z.592473	5	Protected	Oct 21, 2035
InnovitumB Caps(word)	Z.568683	5	Protected	Apr 22, 2034
PORADNIK Smart Mamy	Z.535581	9, 16, 35, 38, 41	Protected	Oct 22, 2031
biorcy ŻYCIA	Z.520701	9, 16, 35, 38, 41	Protected	Nov 10, 2030
InnoferynaLV(word)	Z.473916	5	Protected	Jul 10, 2027

Mark	Protected until
Innofer Immuno(word)	Oct 21, 2035
InnovitumB Caps(word)	Apr 22, 2034
PORADNIK Smart Mamy	Oct 22, 2031
biorcy ŻYCIA	Nov 10, 2030
InnoferynaLV(word)	Jul 10, 2027

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Authorized Representatives

Mauro Ambanelli – Management Board Member

Marta Bojar Czyżewska – Vice President of the Management Board

Manner of representation

Each member of the management board is authorised to independently make declarations and sign on behalf of the company.

Ownership

Owner	Shares	Share value	Stake
Chiesi Farmaceutici S.p.a.	280,000	$3,781,739.60	100%

Beneficial owners

Person	Rights

Competitors

Name	Revenue	Website
Bristol-Myers Squibb Polskasp. z o.o.	$230,722,737.87	bms.com
Bialmedsp. z o.o.	$203,238,055.12	bialmed.pl
Roche Diagnostics Polskasp. z o.o.	$199,208,461.57	roche.pl
Servier Polska Servicessp. z o.o.	$157,143,144.15	servier.pl
Gilead Sciences Polandsp. z o.o.	$150,844,944.19	gilead.com
Zentiva Polskasp. z o.o.	$134,295,523.17	zentiva.pl
LubfarmS.A.	$123,208,945.21	lubfarm.pl
Medezinsp. z o.o.	$107,559,392.19	medezin.pl
Przedsiębiorstwo Zaopatrzenia Farmaceutyczno-Weterynaryjnego Centrowetsp. z o.o.	$92,728,267.63	grupacentrowet.pl
Magnapharm Polandsp. z o.o.	$90,512,785.67	magnapharm.pl

Change history

Date	Event
2020-11-02	Share capital change (5,000,000.00 PLN → 14,000,000.00 PLN)
2017-05-11	Share capital change (247,000.00 PLN → 5,000,000.00 PLN)
2017-05-11	PKD change (Removed: 70.21.Z, 73.12.A, 73.12.B, 73.12.C, 73.12.D, 73.20.Z, 74.90.Z; Added: 46.18.Z, 46.19.Z, 46.46.Z, 46.7, 46.90.Z, 52.10, 72.19.Z)
2015-06-26	Address change (Aleja Solidarności 117, 00-140, Warszawa → Al. Aleje Jerozolimskie 134, 02-305, Warszawa)
2015-06-26	PKD change (Removed: 02.40.Z, 20.42.Z, 21.20.Z, 32.50.Z, 46.46.Z, 47.73.Z, 47.75.Z, 69.20.Z, 72.19.Z, 82.92.Z, 85.32.A, 85.32.B, 85.51.Z, 85.52.Z, 85.59.B, 85.60.Z, 86.90.E)

FAQ

Last updated: 2026-10-07